AU2007210379A1 - Use of TLR3 agonists for the treatment of neurodegenerative disorders - Google Patents

Info

Publication number

AU2007210379A1

AU2007210379A1 AU2007210379A AU2007210379A AU2007210379A1 AU 2007210379 A1 AU2007210379 A1 AU 2007210379A1 AU 2007210379 A AU2007210379 A AU 2007210379A AU 2007210379 A AU2007210379 A AU 2007210379A AU 2007210379 A1 AU2007210379 A1 AU 2007210379A1

Authority

AU

Australia

Prior art keywords

stathmin

tlr3

cells

seq

tissue

Prior art date

2006-02-03

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000556 agonist Substances 0.000 title claims description 88
• 238000011282 treatment Methods 0.000 title claims description 35
• 208000015122 neurodegenerative disease Diseases 0.000 title claims description 25
• 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 title description 3
• 102100024324 Toll-like receptor 3 Human genes 0.000 title 1
• 108050003387 Stathmin Proteins 0.000 claims description 257
• 102000005465 Stathmin Human genes 0.000 claims description 252
• 210000001130 astrocyte Anatomy 0.000 claims description 174
• 108090000623 proteins and genes Proteins 0.000 claims description 139
• 102000004169 proteins and genes Human genes 0.000 claims description 110
• 210000004027 cell Anatomy 0.000 claims description 100
• 230000014509 gene expression Effects 0.000 claims description 98
• 230000004044 response Effects 0.000 claims description 98
• 238000000034 method Methods 0.000 claims description 77
• 150000001875 compounds Chemical class 0.000 claims description 74
• 230000001404 mediated effect Effects 0.000 claims description 64
• 210000001519 tissue Anatomy 0.000 claims description 59
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 54
• 230000000694 effects Effects 0.000 claims description 43
• 239000003814 drug Substances 0.000 claims description 41
• 239000000203 mixture Substances 0.000 claims description 38
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 38
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 34
• 208000035475 disorder Diseases 0.000 claims description 33
• 230000004054 inflammatory process Effects 0.000 claims description 33
• 238000002360 preparation method Methods 0.000 claims description 31
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 31
• 210000002569 neuron Anatomy 0.000 claims description 29
• 239000002243 precursor Substances 0.000 claims description 26
• 230000011664 signaling Effects 0.000 claims description 26
• 230000006378 damage Effects 0.000 claims description 24
• 230000000324 neuroprotective effect Effects 0.000 claims description 24
• 230000003412 degenerative effect Effects 0.000 claims description 23
• 208000014674 injury Diseases 0.000 claims description 22
• 102100028052 Stathmin-3 Human genes 0.000 claims description 21
• 201000010099 disease Diseases 0.000 claims description 21
• 229920001184 polypeptide Polymers 0.000 claims description 21
• 210000002437 synoviocyte Anatomy 0.000 claims description 20
• 230000008439 repair process Effects 0.000 claims description 19
• 230000006870 function Effects 0.000 claims description 18
• 230000000638 stimulation Effects 0.000 claims description 17
• 108091000054 Prion Proteins 0.000 claims description 16
• 102100028051 Stathmin-2 Human genes 0.000 claims description 16
• 230000001154 acute effect Effects 0.000 claims description 16
• 208000027418 Wounds and injury Diseases 0.000 claims description 15
• 201000006417 multiple sclerosis Diseases 0.000 claims description 15
• 230000001684 chronic effect Effects 0.000 claims description 14
• 239000008194 pharmaceutical composition Substances 0.000 claims description 14
• 208000024827 Alzheimer disease Diseases 0.000 claims description 13
• 208000018737 Parkinson disease Diseases 0.000 claims description 13
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 12
• 201000011240 Frontotemporal dementia Diseases 0.000 claims description 11
• 208000023105 Huntington disease Diseases 0.000 claims description 11
• 230000001965 increasing effect Effects 0.000 claims description 11
• 238000011321 prophylaxis Methods 0.000 claims description 11
• 102000029797 Prion Human genes 0.000 claims description 10
• 208000025535 REM sleep behavior disease Diseases 0.000 claims description 10
• 102000008230 Toll-like receptor 3 Human genes 0.000 claims description 10
• 108010060885 Toll-like receptor 3 Proteins 0.000 claims description 10
• 201000006061 fatal familial insomnia Diseases 0.000 claims description 10
• 239000002253 acid Substances 0.000 claims description 9
• 239000003937 drug carrier Substances 0.000 claims description 9
• 210000004498 neuroglial cell Anatomy 0.000 claims description 9
• 241000124008 Mammalia Species 0.000 claims description 8
• 206010028980 Neoplasm Diseases 0.000 claims description 8
• 238000001727 in vivo Methods 0.000 claims description 8
• 230000004936 stimulating effect Effects 0.000 claims description 8
• 208000006011 Stroke Diseases 0.000 claims description 7
• 230000000979 retarding effect Effects 0.000 claims description 7
• 230000006641 stabilisation Effects 0.000 claims description 7
• 210000005222 synovial tissue Anatomy 0.000 claims description 7
• 206010012289 Dementia Diseases 0.000 claims description 6
• 201000011510 cancer Diseases 0.000 claims description 6
• 230000001988 toxicity Effects 0.000 claims description 6
• 231100000419 toxicity Toxicity 0.000 claims description 6
• 208000030507 AIDS Diseases 0.000 claims description 5
• 208000014094 Dystonic disease Diseases 0.000 claims description 5
• 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 5
• 206010019196 Head injury Diseases 0.000 claims description 5
• 206010021138 Hypovolaemic shock Diseases 0.000 claims description 5
• 208000026072 Motor neurone disease Diseases 0.000 claims description 5
• 206010063837 Reperfusion injury Diseases 0.000 claims description 5
• 208000032859 Synucleinopathies Diseases 0.000 claims description 5
• 208000034799 Tauopathies Diseases 0.000 claims description 5
• 208000000323 Tourette Syndrome Diseases 0.000 claims description 5
• 208000016620 Tourette disease Diseases 0.000 claims description 5
• 206010044541 Traumatic shock Diseases 0.000 claims description 5
• 210000005013 brain tissue Anatomy 0.000 claims description 5
• 208000010118 dystonia Diseases 0.000 claims description 5
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
• 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 5
• 206010040560 shock Diseases 0.000 claims description 5
• 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 4
• 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 4
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 4
• 101000697510 Homo sapiens Stathmin-2 Proteins 0.000 claims description 3
• 101000697502 Homo sapiens Stathmin-3 Proteins 0.000 claims 6
• 235000018102 proteins Nutrition 0.000 description 104
• 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 61
• 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 60
• 230000004913 activation Effects 0.000 description 51
• 229940024606 amino acid Drugs 0.000 description 46
• 235000001014 amino acid Nutrition 0.000 description 45
• 102100026236 Interleukin-8 Human genes 0.000 description 42
• 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 41
• 102000002689 Toll-like receptor Human genes 0.000 description 41
• 108020000411 Toll-like receptor Proteins 0.000 description 41
• 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 39
• 102100039360 Toll-like receptor 4 Human genes 0.000 description 39
• 150000001413 amino acids Chemical class 0.000 description 38
• 210000004556 brain Anatomy 0.000 description 36
• 102000004127 Cytokines Human genes 0.000 description 35
• 210000003169 central nervous system Anatomy 0.000 description 35
• 239000002158 endotoxin Substances 0.000 description 35
• 108090000695 Cytokines Proteins 0.000 description 34
• 230000003110 anti-inflammatory effect Effects 0.000 description 33
• 229920006008 lipopolysaccharide Polymers 0.000 description 32
• 230000006698 induction Effects 0.000 description 30
• 210000004443 dendritic cell Anatomy 0.000 description 28
• 239000000047 product Substances 0.000 description 26
• 239000000126 substance Substances 0.000 description 26
• 239000002299 complementary DNA Substances 0.000 description 25
• 230000001225 therapeutic effect Effects 0.000 description 25
• 238000004519 manufacturing process Methods 0.000 description 22
• 206010061218 Inflammation Diseases 0.000 description 21
• 241000699670 Mus sp. Species 0.000 description 21
• 238000012360 testing method Methods 0.000 description 21
• 108050007361 Stathmin-4 Proteins 0.000 description 19
• 229940079593 drug Drugs 0.000 description 18
• 238000002474 experimental method Methods 0.000 description 18
• 102000019034 Chemokines Human genes 0.000 description 17
• 108010012236 Chemokines Proteins 0.000 description 17
• -1 IL-1p Proteins 0.000 description 17
• 102100028049 Stathmin-4 Human genes 0.000 description 16
• 101000831940 Homo sapiens Stathmin Proteins 0.000 description 15
• 230000012010 growth Effects 0.000 description 15
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
• 102000049769 human STMN1 Human genes 0.000 description 14
• 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 13
• 102100024333 Toll-like receptor 2 Human genes 0.000 description 13
• 230000009286 beneficial effect Effects 0.000 description 13
• 210000000274 microglia Anatomy 0.000 description 13
• 230000028327 secretion Effects 0.000 description 13
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 12
• 108010065805 Interleukin-12 Proteins 0.000 description 12
• 102000013462 Interleukin-12 Human genes 0.000 description 12
• 102000004889 Interleukin-6 Human genes 0.000 description 12
• 108090001005 Interleukin-6 Proteins 0.000 description 12
• 230000002950 deficient Effects 0.000 description 12
• 210000002889 endothelial cell Anatomy 0.000 description 12
• 230000003993 interaction Effects 0.000 description 12
• 239000002609 medium Substances 0.000 description 12
• 230000008569 process Effects 0.000 description 12
• 230000000770 proinflammatory effect Effects 0.000 description 12
• RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 11
• 230000027455 binding Effects 0.000 description 11
• 230000002757 inflammatory effect Effects 0.000 description 11
• 239000000523 sample Substances 0.000 description 11
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
• YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 10
• 239000003102 growth factor Substances 0.000 description 10
• 230000019491 signal transduction Effects 0.000 description 10
• 102100040247 Tumor necrosis factor Human genes 0.000 description 9
• 238000007792 addition Methods 0.000 description 9
• 230000015572 biosynthetic process Effects 0.000 description 9
• 239000003636 conditioned culture medium Substances 0.000 description 9
• 230000007850 degeneration Effects 0.000 description 9
• 230000001939 inductive effect Effects 0.000 description 9
• 210000000056 organ Anatomy 0.000 description 9
• 230000001737 promoting effect Effects 0.000 description 9
• 102000005962 receptors Human genes 0.000 description 9
• 108020003175 receptors Proteins 0.000 description 9
• 238000012216 screening Methods 0.000 description 9
• 230000001960 triggered effect Effects 0.000 description 9
• 241000282412 Homo Species 0.000 description 8
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 8
• 238000009825 accumulation Methods 0.000 description 8
• 238000003556 assay Methods 0.000 description 8
• 230000004069 differentiation Effects 0.000 description 8
• 230000008733 trauma Effects 0.000 description 8
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 7
• 102000003814 Interleukin-10 Human genes 0.000 description 7
• 108090000174 Interleukin-10 Proteins 0.000 description 7
• 241001529936 Murinae Species 0.000 description 7
• 230000003510 anti-fibrotic effect Effects 0.000 description 7
• 239000001963 growth medium Substances 0.000 description 7
• 230000003834 intracellular effect Effects 0.000 description 7
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
• 239000000546 pharmaceutical excipient Substances 0.000 description 7
• 230000004083 survival effect Effects 0.000 description 7
• 102100034452 Alternative prion protein Human genes 0.000 description 6
• 108020004635 Complementary DNA Proteins 0.000 description 6
• 241001465754 Metazoa Species 0.000 description 6
• 241000700159 Rattus Species 0.000 description 6
• 108020004459 Small interfering RNA Proteins 0.000 description 6
• 230000003213 activating effect Effects 0.000 description 6
• 238000004458 analytical method Methods 0.000 description 6
• 230000033228 biological regulation Effects 0.000 description 6
• 230000010261 cell growth Effects 0.000 description 6
• 230000001413 cellular effect Effects 0.000 description 6
• 239000012228 culture supernatant Substances 0.000 description 6
• 230000006866 deterioration Effects 0.000 description 6
• 210000002950 fibroblast Anatomy 0.000 description 6
• 238000009396 hybridization Methods 0.000 description 6
• 208000027866 inflammatory disease Diseases 0.000 description 6
• 239000003446 ligand Substances 0.000 description 6
• 239000003550 marker Substances 0.000 description 6
• 210000003061 neural cell Anatomy 0.000 description 6
• 239000013612 plasmid Substances 0.000 description 6
• 230000002265 prevention Effects 0.000 description 6
• 230000035755 proliferation Effects 0.000 description 6
• 230000009719 regenerative response Effects 0.000 description 6
• 230000001105 regulatory effect Effects 0.000 description 6
• 238000010186 staining Methods 0.000 description 6
• 230000017423 tissue regeneration Effects 0.000 description 6
• 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 5
• 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 5
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
• 108010065637 Interleukin-23 Proteins 0.000 description 5
• 102000013264 Interleukin-23 Human genes 0.000 description 5
• 108090000978 Interleukin-4 Proteins 0.000 description 5
• 102000004388 Interleukin-4 Human genes 0.000 description 5
• 241000699666 Mus <mouse, genus> Species 0.000 description 5
• 108700008625 Reporter Genes Proteins 0.000 description 5
• 108050007363 Stathmin-3 Proteins 0.000 description 5
• 125000000539 amino acid group Chemical group 0.000 description 5
• 238000010171 animal model Methods 0.000 description 5
• 230000000692 anti-sense effect Effects 0.000 description 5
• 230000037396 body weight Effects 0.000 description 5
• 230000012292 cell migration Effects 0.000 description 5
• 230000003399 chemotactic effect Effects 0.000 description 5
• 230000001419 dependent effect Effects 0.000 description 5
• 238000011161 development Methods 0.000 description 5
• 230000018109 developmental process Effects 0.000 description 5
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
• 210000003630 histaminocyte Anatomy 0.000 description 5
• 230000003902 lesion Effects 0.000 description 5
• 230000035800 maturation Effects 0.000 description 5
• 230000007246 mechanism Effects 0.000 description 5
• 210000004379 membrane Anatomy 0.000 description 5
• 239000012528 membrane Substances 0.000 description 5
• 108020004999 messenger RNA Proteins 0.000 description 5
• 210000001616 monocyte Anatomy 0.000 description 5
• 230000006576 neuronal survival Effects 0.000 description 5
• 210000004248 oligodendroglia Anatomy 0.000 description 5
• 239000002953 phosphate buffered saline Substances 0.000 description 5
• 230000026731 phosphorylation Effects 0.000 description 5
• 238000006366 phosphorylation reaction Methods 0.000 description 5
• 230000008458 response to injury Effects 0.000 description 5
• 150000003839 salts Chemical class 0.000 description 5
• 229940124597 therapeutic agent Drugs 0.000 description 5
• 208000003174 Brain Neoplasms Diseases 0.000 description 4
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 4
• 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 4
• 238000002965 ELISA Methods 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 4
• 206010018341 Gliosis Diseases 0.000 description 4
• 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 4
• 101000617546 Homo sapiens Presenilin-2 Proteins 0.000 description 4
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
• 102100022036 Presenilin-2 Human genes 0.000 description 4
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
• 108050008927 Stathmin-2 Proteins 0.000 description 4
• 238000010521 absorption reaction Methods 0.000 description 4
• 238000000540 analysis of variance Methods 0.000 description 4
• 230000002491 angiogenic effect Effects 0.000 description 4
• 239000000427 antigen Substances 0.000 description 4
• 108091007433 antigens Proteins 0.000 description 4
• 102000036639 antigens Human genes 0.000 description 4
• 238000013459 approach Methods 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 208000015114 central nervous system disease Diseases 0.000 description 4
• 230000001276 controlling effect Effects 0.000 description 4
• 230000000254 damaging effect Effects 0.000 description 4
• 230000034994 death Effects 0.000 description 4
• 230000007423 decrease Effects 0.000 description 4
• 238000006731 degradation reaction Methods 0.000 description 4
• 238000001514 detection method Methods 0.000 description 4
• 229940088598 enzyme Drugs 0.000 description 4
• 235000013305 food Nutrition 0.000 description 4
• 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 4
• 230000007387 gliosis Effects 0.000 description 4
• 238000000338 in vitro Methods 0.000 description 4
• 230000002401 inhibitory effect Effects 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 210000004901 leucine-rich repeat Anatomy 0.000 description 4
• 238000005259 measurement Methods 0.000 description 4
• 238000013508 migration Methods 0.000 description 4
• 210000000653 nervous system Anatomy 0.000 description 4
• 230000001537 neural effect Effects 0.000 description 4
• 230000004112 neuroprotection Effects 0.000 description 4
• 230000037361 pathway Effects 0.000 description 4
• 239000000816 peptidomimetic Substances 0.000 description 4
• 239000000825 pharmaceutical preparation Substances 0.000 description 4
• 102000040430 polynucleotide Human genes 0.000 description 4
• 108091033319 polynucleotide Proteins 0.000 description 4
• 239000002157 polynucleotide Substances 0.000 description 4
• 230000000069 prophylactic effect Effects 0.000 description 4
• 239000000243 solution Substances 0.000 description 4
• 230000035899 viability Effects 0.000 description 4
• 230000029663 wound healing Effects 0.000 description 4
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 241000894006 Bacteria Species 0.000 description 3
• 208000016192 Demyelinating disease Diseases 0.000 description 3
• 206010012305 Demyelination Diseases 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
• 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 3
• 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 3
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
• 102000029749 Microtubule Human genes 0.000 description 3
• 108091022875 Microtubule Proteins 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• 102000007982 Phosphoproteins Human genes 0.000 description 3
• 108010089430 Phosphoproteins Proteins 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• 241000283984 Rodentia Species 0.000 description 3
• 102000018238 Stathmin-3 Human genes 0.000 description 3
• 102000018239 Stathmin-4 Human genes 0.000 description 3
• 102100027010 Toll-like receptor 1 Human genes 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
• 230000002378 acidificating effect Effects 0.000 description 3
• 210000001056 activated astrocyte Anatomy 0.000 description 3
• 125000001931 aliphatic group Chemical group 0.000 description 3
• 150000001408 amides Chemical class 0.000 description 3
• 210000003484 anatomy Anatomy 0.000 description 3
• 230000033115 angiogenesis Effects 0.000 description 3
• 238000003491 array Methods 0.000 description 3
• 206010003246 arthritis Diseases 0.000 description 3
• 235000003704 aspartic acid Nutrition 0.000 description 3
• 210000003050 axon Anatomy 0.000 description 3
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 238000000978 circular dichroism spectroscopy Methods 0.000 description 3
• 239000000356 contaminant Substances 0.000 description 3
• 230000001054 cortical effect Effects 0.000 description 3
• 230000001086 cytosolic effect Effects 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 230000007547 defect Effects 0.000 description 3
• UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
• 230000003828 downregulation Effects 0.000 description 3
• 230000013020 embryo development Effects 0.000 description 3
• 210000002919 epithelial cell Anatomy 0.000 description 3
• 238000002825 functional assay Methods 0.000 description 3
• 230000002518 glial effect Effects 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 230000003053 immunization Effects 0.000 description 3
• 238000002649 immunization Methods 0.000 description 3
• 230000001771 impaired effect Effects 0.000 description 3
• 230000001976 improved effect Effects 0.000 description 3
• 230000004968 inflammatory condition Effects 0.000 description 3
• 230000000977 initiatory effect Effects 0.000 description 3
• 238000003780 insertion Methods 0.000 description 3
• 230000037431 insertion Effects 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 210000004072 lung Anatomy 0.000 description 3
• 210000004962 mammalian cell Anatomy 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 210000004688 microtubule Anatomy 0.000 description 3
• 230000005012 migration Effects 0.000 description 3
• 230000003278 mimic effect Effects 0.000 description 3
• DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 3
• 230000000626 neurodegenerative effect Effects 0.000 description 3
• 150000007523 nucleic acids Chemical group 0.000 description 3
• 239000002674 ointment Substances 0.000 description 3
• 230000036542 oxidative stress Effects 0.000 description 3
• 230000036961 partial effect Effects 0.000 description 3
• 244000052769 pathogen Species 0.000 description 3
• 210000001428 peripheral nervous system Anatomy 0.000 description 3
• 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 3
• 230000003389 potentiating effect Effects 0.000 description 3
• 230000001023 pro-angiogenic effect Effects 0.000 description 3
• 230000002285 radioactive effect Effects 0.000 description 3
• 238000011084 recovery Methods 0.000 description 3
• 238000003757 reverse transcription PCR Methods 0.000 description 3
• 238000007423 screening assay Methods 0.000 description 3
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 238000006467 substitution reaction Methods 0.000 description 3
• 230000008093 supporting effect Effects 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 230000000451 tissue damage Effects 0.000 description 3
• 231100000827 tissue damage Toxicity 0.000 description 3
• 238000001890 transfection Methods 0.000 description 3
• 230000014567 type I interferon production Effects 0.000 description 3
• 239000003981 vehicle Substances 0.000 description 3
• 230000029812 viral genome replication Effects 0.000 description 3
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
• WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 2
• BGWLYQZDNFIFRX-UHFFFAOYSA-N 5-[3-[2-[3-(3,8-diamino-6-phenylphenanthridin-5-ium-5-yl)propylamino]ethylamino]propyl]-6-phenylphenanthridin-5-ium-3,8-diamine;dichloride Chemical compound [Cl-].[Cl-].C=1C(N)=CC=C(C2=CC=C(N)C=C2[N+]=2CCCNCCNCCC[N+]=3C4=CC(N)=CC=C4C4=CC=C(N)C=C4C=3C=3C=CC=CC=3)C=1C=2C1=CC=CC=C1 BGWLYQZDNFIFRX-UHFFFAOYSA-N 0.000 description 2
• 208000031277 Amaurotic familial idiocy Diseases 0.000 description 2
• 206010003571 Astrocytoma Diseases 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
• 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
• 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 2
• ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
• 102100040897 Embryonic growth/differentiation factor 1 Human genes 0.000 description 2
• 241000588724 Escherichia coli Species 0.000 description 2
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
• 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 2
• 208000003098 Ganglion Cysts Diseases 0.000 description 2
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
• 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 2
• 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 2
• 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• 108010014726 Interferon Type I Proteins 0.000 description 2
• 102000002227 Interferon Type I Human genes 0.000 description 2
• 102000000589 Interleukin-1 Human genes 0.000 description 2
• 108010002352 Interleukin-1 Proteins 0.000 description 2
• 102000003815 Interleukin-11 Human genes 0.000 description 2
• 108090000177 Interleukin-11 Proteins 0.000 description 2
• 108010002616 Interleukin-5 Proteins 0.000 description 2
• 102100039897 Interleukin-5 Human genes 0.000 description 2
• 108010002335 Interleukin-9 Proteins 0.000 description 2
• 102000000585 Interleukin-9 Human genes 0.000 description 2
• 238000012313 Kruskal-Wallis test Methods 0.000 description 2
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical class CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 208000002569 Machado-Joseph Disease Diseases 0.000 description 2
• 102100025136 Macrosialin Human genes 0.000 description 2
• 208000000172 Medulloblastoma Diseases 0.000 description 2
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
• 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
• 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 2
• 206010029350 Neurotoxicity Diseases 0.000 description 2
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
• 201000010133 Oligodendroglioma Diseases 0.000 description 2
• 108091034117 Oligonucleotide Proteins 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 102100039277 Pleiotrophin Human genes 0.000 description 2
• LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
• 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 208000005400 Synovial Cyst Diseases 0.000 description 2
• 210000001744 T-lymphocyte Anatomy 0.000 description 2
• 206010044221 Toxic encephalopathy Diseases 0.000 description 2
• 206010052779 Transplant rejections Diseases 0.000 description 2
• 102000004243 Tubulin Human genes 0.000 description 2
• 108090000704 Tubulin Proteins 0.000 description 2
• 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 2
• 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 2
• 241000700605 Viruses Species 0.000 description 2
• 206010052428 Wound Diseases 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 208000026935 allergic disease Diseases 0.000 description 2
• 230000007815 allergy Effects 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• 230000000845 anti-microbial effect Effects 0.000 description 2
• 239000000074 antisense oligonucleotide Substances 0.000 description 2
• 238000012230 antisense oligonucleotides Methods 0.000 description 2
• 230000006907 apoptotic process Effects 0.000 description 2
• 235000009582 asparagine Nutrition 0.000 description 2
• 238000011888 autopsy Methods 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 230000006399 behavior Effects 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 230000008499 blood brain barrier function Effects 0.000 description 2
• 210000001218 blood-brain barrier Anatomy 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 2
• BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 2
• 238000004364 calculation method Methods 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 150000001720 carbohydrates Chemical class 0.000 description 2
• 235000014633 carbohydrates Nutrition 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 230000030833 cell death Effects 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 125000003636 chemical group Chemical group 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 238000001142 circular dichroism spectrum Methods 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 239000013078 crystal Substances 0.000 description 2
• 238000012258 culturing Methods 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• 108010057085 cytokine receptors Proteins 0.000 description 2
• 230000005860 defense response to virus Effects 0.000 description 2
• 230000006735 deficit Effects 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• 230000003210 demyelinating effect Effects 0.000 description 2
• 210000001787 dendrite Anatomy 0.000 description 2
• 238000000502 dialysis Methods 0.000 description 2
• 235000015872 dietary supplement Nutrition 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• 239000006185 dispersion Substances 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 230000002708 enhancing effect Effects 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• 210000002744 extracellular matrix Anatomy 0.000 description 2
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 description 2
• 210000004602 germ cell Anatomy 0.000 description 2
• 150000004676 glycans Chemical class 0.000 description 2
• 239000005090 green fluorescent protein Substances 0.000 description 2
• 102000045716 human TLR3 Human genes 0.000 description 2
• 210000005260 human cell Anatomy 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 230000002779 inactivation Effects 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 230000002458 infectious effect Effects 0.000 description 2
• 230000015788 innate immune response Effects 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 239000007928 intraperitoneal injection Substances 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 210000000265 leukocyte Anatomy 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 210000001161 mammalian embryo Anatomy 0.000 description 2
• 206010027191 meningioma Diseases 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
• 229930182817 methionine Natural products 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 230000009456 molecular mechanism Effects 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 210000005036 nerve Anatomy 0.000 description 2
• 230000004770 neurodegeneration Effects 0.000 description 2
• 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 description 2
• 230000002887 neurotoxic effect Effects 0.000 description 2
• 231100000228 neurotoxicity Toxicity 0.000 description 2
• 230000007135 neurotoxicity Effects 0.000 description 2
• 102000039446 nucleic acids Human genes 0.000 description 2
• 108020004707 nucleic acids Proteins 0.000 description 2
• 229960002378 oftasceine Drugs 0.000 description 2
• 239000006072 paste Substances 0.000 description 2
• VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 229920001282 polysaccharide Polymers 0.000 description 2
• 239000005017 polysaccharide Substances 0.000 description 2
• 239000013641 positive control Substances 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 230000004224 protection Effects 0.000 description 2
• 230000002685 pulmonary effect Effects 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 230000008929 regeneration Effects 0.000 description 2
• 238000011069 regeneration method Methods 0.000 description 2
• 230000000717 retained effect Effects 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• 231100000241 scar Toxicity 0.000 description 2
• 210000003491 skin Anatomy 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 239000006228 supernatant Substances 0.000 description 2
• 239000013589 supplement Substances 0.000 description 2
• 230000003319 supportive effect Effects 0.000 description 2
• ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
• 210000001541 thymus gland Anatomy 0.000 description 2
• 239000004474 valine Chemical class 0.000 description 2
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
• 210000004885 white matter Anatomy 0.000 description 2
• WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• 208000011403 Alexander disease Diseases 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 241000272525 Anas platyrhynchos Species 0.000 description 1
• 206010002660 Anoxia Diseases 0.000 description 1
• 241000976983 Anoxia Species 0.000 description 1
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
• 102000007371 Ataxin-3 Human genes 0.000 description 1
• 102000014461 Ataxins Human genes 0.000 description 1
• 108010078286 Ataxins Proteins 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
• 208000014644 Brain disease Diseases 0.000 description 1
• 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
• 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
• 102100036153 C-X-C motif chemokine 6 Human genes 0.000 description 1
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
• 208000022526 Canavan disease Diseases 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 206010008025 Cerebellar ataxia Diseases 0.000 description 1
• WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
• 208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 description 1
• 208000010200 Cockayne syndrome Diseases 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 241000195493 Cryptophyta Species 0.000 description 1
• 150000008574 D-amino acids Chemical class 0.000 description 1
• 229920002271 DEAE-Sepharose Polymers 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 238000008157 ELISA kit Methods 0.000 description 1
• 101710197615 Embryonic growth/differentiation factor 1 Proteins 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 206010049020 Encephalitis periaxialis diffusa Diseases 0.000 description 1
• 208000032274 Encephalopathy Diseases 0.000 description 1
• 102100032450 Endothelial differentiation-related factor 1 Human genes 0.000 description 1
• 230000010665 Enzyme Interactions Effects 0.000 description 1
• 101710114538 Ephrin type-B receptor 1 Proteins 0.000 description 1
• 102100030779 Ephrin type-B receptor 1 Human genes 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 102000044591 ErbB-4 Receptor Human genes 0.000 description 1
• 108700039887 Essential Genes Proteins 0.000 description 1
• 108091008794 FGF receptors Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
• 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
• 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
• 102100037362 Fibronectin Human genes 0.000 description 1
• 108010067306 Fibronectins Proteins 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 1
• 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
• 229940122459 Glutamate antagonist Drugs 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
• 101000947177 Homo sapiens C-X-C motif chemokine 6 Proteins 0.000 description 1
• 101000893552 Homo sapiens Embryonic growth/differentiation factor 1 Proteins 0.000 description 1
• 101001016384 Homo sapiens Endothelial differentiation-related factor 1 Proteins 0.000 description 1
• 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
• 101000697529 Homo sapiens Stathmin-4 Proteins 0.000 description 1
• 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 1
• 208000017178 Hypoglossal Nerve injury Diseases 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 108010032038 Interferon Regulatory Factor-3 Proteins 0.000 description 1
• 102100026720 Interferon beta Human genes 0.000 description 1
• 108010005716 Interferon beta-1a Proteins 0.000 description 1
• 102100036981 Interferon regulatory factor 1 Human genes 0.000 description 1
• 108090000890 Interferon regulatory factor 1 Proteins 0.000 description 1
• 102100029843 Interferon regulatory factor 3 Human genes 0.000 description 1
• 102100038069 Interferon regulatory factor 8 Human genes 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• 102100039065 Interleukin-1 beta Human genes 0.000 description 1
• 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
• 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
• 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 1
• 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 101150113031 Jag1 gene Proteins 0.000 description 1
• 208000027747 Kennedy disease Diseases 0.000 description 1
• 208000028226 Krabbe disease Diseases 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 1
• 208000009829 Lewy Body Disease Diseases 0.000 description 1
• 201000002832 Lewy body dementia Diseases 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• 239000005089 Luciferase Substances 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 208000001089 Multiple system atrophy Diseases 0.000 description 1
• 208000023178 Musculoskeletal disease Diseases 0.000 description 1
• 102000006386 Myelin Proteins Human genes 0.000 description 1
• 108010083674 Myelin Proteins Proteins 0.000 description 1
• 102100026784 Myelin proteolipid protein Human genes 0.000 description 1
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 108010025020 Nerve Growth Factor Proteins 0.000 description 1
• 102000007072 Nerve Growth Factors Human genes 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• 102000003683 Neurotrophin-4 Human genes 0.000 description 1
• 108090000099 Neurotrophin-4 Proteins 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 108010038807 Oligopeptides Proteins 0.000 description 1
• 102000015636 Oligopeptides Human genes 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108010043958 Peptoids Proteins 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 108010076504 Protein Sorting Signals Proteins 0.000 description 1
• 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
• 208000028017 Psychotic disease Diseases 0.000 description 1
• 238000011529 RT qPCR Methods 0.000 description 1
• 101000595041 Rattus norvegicus Podocalyxin Proteins 0.000 description 1
• 230000010799 Receptor Interactions Effects 0.000 description 1
• 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 208000005587 Refsum Disease Diseases 0.000 description 1
• 108091006629 SLC13A2 Proteins 0.000 description 1
• 208000021811 Sandhoff disease Diseases 0.000 description 1
• 208000021235 Schilder disease Diseases 0.000 description 1
• 238000012300 Sequence Analysis Methods 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
• 102100024237 Stathmin Human genes 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 206010048327 Supranuclear palsy Diseases 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 241000656145 Thyrsites atun Species 0.000 description 1
• 208000026062 Tissue disease Diseases 0.000 description 1
• 102100039357 Toll-like receptor 5 Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 102000018594 Tumour necrosis factor Human genes 0.000 description 1
• 108050007852 Tumour necrosis factor Proteins 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
• 108091008605 VEGF receptors Proteins 0.000 description 1
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 102100035140 Vitronectin Human genes 0.000 description 1
• 108010031318 Vitronectin Proteins 0.000 description 1
• 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
• 241000269370 Xenopus <genus> Species 0.000 description 1
• 229920000392 Zymosan Polymers 0.000 description 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
• 238000002679 ablation Methods 0.000 description 1
• 235000011054 acetic acid Nutrition 0.000 description 1
• 108020002494 acetyltransferase Proteins 0.000 description 1
• 102000005421 acetyltransferase Human genes 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 230000033289 adaptive immune response Effects 0.000 description 1
• 230000004721 adaptive immunity Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 208000030597 adult Refsum disease Diseases 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 125000003545 alkoxy group Chemical group 0.000 description 1
• 125000003282 alkyl amino group Chemical group 0.000 description 1
• 125000004414 alkyl thio group Chemical group 0.000 description 1
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 150000001409 amidines Chemical class 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• 210000004727 amygdala Anatomy 0.000 description 1
• 229940035676 analgesics Drugs 0.000 description 1
• 239000002870 angiogenesis inducing agent Substances 0.000 description 1
• 238000005571 anion exchange chromatography Methods 0.000 description 1
• 230000007953 anoxia Effects 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 239000000730 antalgic agent Substances 0.000 description 1
• 230000003266 anti-allergic effect Effects 0.000 description 1
• 230000001772 anti-angiogenic effect Effects 0.000 description 1
• 230000000665 anti-chemotactic effect Effects 0.000 description 1
• 230000001430 anti-depressive effect Effects 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 230000005809 anti-tumor immunity Effects 0.000 description 1
• 239000000935 antidepressant agent Substances 0.000 description 1
• 229940005513 antidepressants Drugs 0.000 description 1
• 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 239000012062 aqueous buffer Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 150000004982 aromatic amines Chemical class 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 150000001508 asparagines Chemical class 0.000 description 1
• 230000003140 astrocytic effect Effects 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 230000003190 augmentative effect Effects 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
• 229940003504 avonex Drugs 0.000 description 1
• 230000007845 axonopathy Effects 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 150000001576 beta-amino acids Chemical class 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 230000029918 bioluminescence Effects 0.000 description 1
• 238000005415 bioluminescence Methods 0.000 description 1
• 239000000090 biomarker Substances 0.000 description 1
• 210000001172 blastoderm Anatomy 0.000 description 1
• 239000002981 blocking agent Substances 0.000 description 1
• 230000036770 blood supply Effects 0.000 description 1
• 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
• 150000003857 carboxamides Chemical class 0.000 description 1
• 210000005056 cell body Anatomy 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 208000037887 cell injury Diseases 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 108091092328 cellular RNA Proteins 0.000 description 1
• 230000030570 cellular localization Effects 0.000 description 1
• 230000007248 cellular mechanism Effects 0.000 description 1
• 230000033077 cellular process Effects 0.000 description 1
• 230000007073 chemical hydrolysis Effects 0.000 description 1
• 238000001311 chemical methods and process Methods 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 239000003795 chemical substances by application Substances 0.000 description 1
• WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
• 229960005091 chloramphenicol Drugs 0.000 description 1
• 238000013375 chromatographic separation Methods 0.000 description 1
• 229930016911 cinnamic acid Natural products 0.000 description 1
• 235000013985 cinnamic acid Nutrition 0.000 description 1
• 230000002060 circadian Effects 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 230000001010 compromised effect Effects 0.000 description 1
• 230000001143 conditioned effect Effects 0.000 description 1
• 230000003750 conditioning effect Effects 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 230000009537 cortical lesion Effects 0.000 description 1
• 210000003618 cortical neuron Anatomy 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 102000003675 cytokine receptors Human genes 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 239000000824 cytostatic agent Substances 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 231100000858 damage to nervous tissue Toxicity 0.000 description 1
• 230000004665 defense response Effects 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 238000000188 dichroism spectroscopy Methods 0.000 description 1
• 210000002249 digestive system Anatomy 0.000 description 1
• 229940043279 diisopropylamine Drugs 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 239000008298 dragée Substances 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 210000002257 embryonic structure Anatomy 0.000 description 1
• 239000008393 encapsulating agent Substances 0.000 description 1
• 230000012202 endocytosis Effects 0.000 description 1
• 230000008497 endothelial barrier function Effects 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 230000009144 enzymatic modification Effects 0.000 description 1
• 210000003059 ependyma Anatomy 0.000 description 1
• 125000004185 ester group Chemical group 0.000 description 1
• AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
• 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 239000011536 extraction buffer Substances 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 230000003176 fibrotic effect Effects 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 239000012737 fresh medium Substances 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 238000010230 functional analysis Methods 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 210000000609 ganglia Anatomy 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 239000003825 glutamate receptor antagonist Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 235000004554 glutamine Nutrition 0.000 description 1
• 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
• 210000004884 grey matter Anatomy 0.000 description 1
• 210000000020 growth cone Anatomy 0.000 description 1
• 102000028718 growth factor binding proteins Human genes 0.000 description 1
• 108091009353 growth factor binding proteins Proteins 0.000 description 1
• 230000009931 harmful effect Effects 0.000 description 1
• 230000008642 heat stress Effects 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 125000005842 heteroatom Chemical group 0.000 description 1
• 238000013537 high throughput screening Methods 0.000 description 1
• 238000012188 high-throughput screening assay Methods 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
• 238000010562 histological examination Methods 0.000 description 1
• 239000000710 homodimer Substances 0.000 description 1
• 235000003642 hunger Nutrition 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• 238000000126 in silico method Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 230000004941 influx Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 108010051621 interferon regulatory factor-8 Proteins 0.000 description 1
• XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
• 229940096397 interleukin-8 Drugs 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 230000004068 intracellular signaling Effects 0.000 description 1
• 230000010189 intracellular transport Effects 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 210000005067 joint tissue Anatomy 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 201000010901 lateral sclerosis Diseases 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 230000027928 long-term synaptic potentiation Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 210000005210 lymphoid organ Anatomy 0.000 description 1
• 235000018977 lysine Nutrition 0.000 description 1
• 230000002132 lysosomal effect Effects 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 235000013372 meat Nutrition 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
• 125000005699 methyleneoxy group Chemical group [H]C([H])([*:1])O[*:2] 0.000 description 1
• 230000002025 microglial effect Effects 0.000 description 1
• 230000008880 microtubule cytoskeleton organization Effects 0.000 description 1
• 230000001617 migratory effect Effects 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 230000011278 mitosis Effects 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 108091005601 modified peptides Proteins 0.000 description 1
• 102000035118 modified proteins Human genes 0.000 description 1
• 108091005573 modified proteins Proteins 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 230000007659 motor function Effects 0.000 description 1
• 208000005264 motor neuron disease Diseases 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 210000004400 mucous membrane Anatomy 0.000 description 1
• 238000002887 multiple sequence alignment Methods 0.000 description 1
• 210000002487 multivesicular body Anatomy 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 210000005012 myelin Anatomy 0.000 description 1
• 210000004897 n-terminal region Anatomy 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
• 210000002241 neurite Anatomy 0.000 description 1
• 230000004766 neurogenesis Effects 0.000 description 1
• 230000003959 neuroinflammation Effects 0.000 description 1
• 230000004031 neuronal differentiation Effects 0.000 description 1
• 230000009207 neuronal maturation Effects 0.000 description 1
• 208000002040 neurosyphilis Diseases 0.000 description 1
• 231100000189 neurotoxic Toxicity 0.000 description 1
• 229940097998 neurotrophin 4 Drugs 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 239000002417 nutraceutical Substances 0.000 description 1
• 235000021436 nutraceutical agent Nutrition 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 230000000414 obstructive effect Effects 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 210000000956 olfactory bulb Anatomy 0.000 description 1
• 238000006384 oligomerization reaction Methods 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• 238000001543 one-way ANOVA Methods 0.000 description 1
• 229940005483 opioid analgesics Drugs 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 239000006179 pH buffering agent Substances 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 230000001769 paralizing effect Effects 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 210000004976 peripheral blood cell Anatomy 0.000 description 1
• 208000027232 peripheral nervous system disease Diseases 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• 208000022821 personality disease Diseases 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 239000013600 plasmid vector Substances 0.000 description 1
• 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 125000003367 polycyclic group Chemical group 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 208000032207 progressive 1 supranuclear palsy Diseases 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 201000001514 prostate carcinoma Diseases 0.000 description 1
• 229940076376 protein agonist Drugs 0.000 description 1
• 239000000007 protein synthesis inhibitor Substances 0.000 description 1
• 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 229940107700 pyruvic acid Drugs 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 238000003753 real-time PCR Methods 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 239000013643 reference control Substances 0.000 description 1
• 230000001172 regenerating effect Effects 0.000 description 1
• 238000009877 rendering Methods 0.000 description 1
• 230000008263 repair mechanism Effects 0.000 description 1
• 230000003252 repetitive effect Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000028617 response to DNA damage stimulus Effects 0.000 description 1
• 230000002207 retinal effect Effects 0.000 description 1
• 238000010839 reverse transcription Methods 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 238000011808 rodent model Methods 0.000 description 1
• 238000009738 saturating Methods 0.000 description 1
• 230000036573 scar formation Effects 0.000 description 1
• 201000000980 schizophrenia Diseases 0.000 description 1
• 210000004116 schwann cell Anatomy 0.000 description 1
• 238000003345 scintillation counting Methods 0.000 description 1
• 230000001932 seasonal effect Effects 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 206010040882 skin lesion Diseases 0.000 description 1
• 231100000444 skin lesion Toxicity 0.000 description 1
• 239000004055 small Interfering RNA Substances 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
• 239000012453 solvate Substances 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 208000002320 spinal muscular atrophy Diseases 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 230000037351 starvation Effects 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 230000004960 subcellular localization Effects 0.000 description 1
• 230000002739 subcortical effect Effects 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
• 210000002222 superior cervical ganglion Anatomy 0.000 description 1
• 230000001502 supplementing effect Effects 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 208000002025 tabes dorsalis Diseases 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 238000005382 thermal cycling Methods 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 150000007970 thio esters Chemical class 0.000 description 1
• 230000002992 thymic effect Effects 0.000 description 1
• 230000008354 tissue degradation Effects 0.000 description 1
• 230000025366 tissue development Effects 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 230000008736 traumatic injury Effects 0.000 description 1
• 125000005270 trialkylamine group Chemical group 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 231100000397 ulcer Toxicity 0.000 description 1
• 238000005199 ultracentrifugation Methods 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 238000002255 vaccination Methods 0.000 description 1
• 229960005486 vaccine Drugs 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 239000013598 vector Substances 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 238000011179 visual inspection Methods 0.000 description 1
• 238000012800 visualization Methods 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1